EGFR and pancreatic neoplasm: Liquid biopsy enables the identification of tumour mutations responsible for tumour response to treatment (i.e. epidermal growth factor receptor [EGFR] in NSCLC), primary or acquired resistance to treatment (i.e. RAS gene mutation in colorectal cancer), and monitoring of tumour dynamics during treatment (i.e. KRAS gene mutation in pancreatic cancer).